Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance
| Autor: | George Andrew Freeman, Jill R. Cowan, Marty St. Clair, Karen Rene Romines, Robert J. Harvey, Lee T. Schaller, Robert G. Ferris, Steven A. Short, Lawrence R. Boone, Joseph H. Chan, Jeffrey H. Tidwell, Richard Hazen |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Efavirenz
Nevirapine Anti-HIV Agents Recombinant virus Antiviral Agents Virus Cell Line chemistry.chemical_compound Serial passage Antiretroviral Therapy Highly Active Drug Resistance Viral Nitriles medicine Humans Pharmacology (medical) Protease inhibitor (pharmacology) Pharmacology Acquired Immunodeficiency Syndrome Sulfonamides biology Reverse-transcriptase inhibitor Dose-Response Relationship Drug biology.organism_classification Virology HIV Reverse Transcriptase Infectious Diseases Phenotype chemistry Lentivirus HIV-1 Reverse Transcriptase Inhibitors Drug Therapy Combination medicine.drug |
| Zdroj: | Antimicrobial agents and chemotherapy. 49(11) |
| ISSN: | 0066-4804 |
| Popis: | GW678248, a novel nonnucleoside reverse transcriptase inhibitor, has been evaluated for anti-human immunodeficiency virus activity in a variety of in vitro assays against laboratory strains and clinical isolates. When GW678248 was tested in combination with approved drugs in the nucleoside and nucleotide reverse transcriptase inhibitor classes or the protease inhibitor class, the antiviral activities were either synergistic or additive. When GW678248 was tested in combination with approved drugs in the nonnucleoside reverse transcriptase inhibitor class, the antiviral activities were either additive or slightly antagonistic. Clinical isolates from antiretroviral drug-experienced patients were selected for evaluation of sensitivity to GW678248 in a recombinant virus assay. Efavirenz (EFV) and nevirapine (NVP) had ≥10-fold increases in their 50% inhibitory concentrations (IC 50 s) for 85% and 98% of the 55 selected isolates, respectively, whereas GW678248 had a ≥10-fold increase in the IC 50 for only 17% of these isolates. Thus, 81 to 83% of the EFV- and/or NVP-resistant viruses from this data set were susceptible to GW678248. Virus populations resistant to GW678248 were selected by in vitro dose-escalating serial passage. Resistant progeny viruses recovered after eight passages had amino acid substitutions V106I, E138K, and P236L in the reverse transcriptase-coding region in one passage series and amino acid substitutions K102E, V106A, and P236L in a second passage series. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|